Selected research
Industry Research
Blood Plasma Derivatives Industry Research Report 2026
Market perspective
The global Blood Plasma Derivatives market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Blood Plasma Derivatives market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Blood Plasma Derivatives market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Blood Plasma Derivatives market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Blood Plasma Derivatives include Yuanda Shuyang, Takeda, Weiguang Bio, Tiantan Bio, CBPO, Shuanglin Bio, RAAS, Nanyue Bio and Hualan Bio, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Blood Plasma Derivatives market in terms of revenue (US$ million) and, where applicable, service volume (k units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Blood Plasma Derivatives.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Blood Plasma Derivatives Market by Company
Yuanda Shuyang
Takeda
Weiguang Bio
Tiantan Bio
CBPO
Shuanglin Bio
RAAS
Nanyue Bio
Hualan Bio
Boya Bio
Octapharma
LFB Group
KM Biologics
Kedrion
Grifols
CSL
BPL
Biotest
Blood Plasma Derivatives Segment by Type
Albumin
Coagulation Factor
Immune Globulin
Other
Blood Plasma Derivatives Segment by Application
Hospital
Retail Pharmacy
Other
Blood Plasma Derivatives Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Blood Plasma Derivatives market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Blood Plasma Derivatives and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Blood Plasma Derivatives.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Blood Plasma Derivatives companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Albumin
- Coagulation Factor
- Immune Globulin
- Other
Applications
- Hospital
- Retail Pharmacy
- Other
Companies covered
- Yuanda Shuyang
- Takeda
- Weiguang Bio
- Tiantan Bio
- CBPO
- Shuanglin Bio
- RAAS
- Nanyue Bio
- Hualan Bio
- Boya Bio
- Octapharma
- LFB Group
- KM Biologics
- Kedrion
- Grifols
- CSL
- BPL
- Biotest
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Blood Plasma Derivatives by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Albumin
- 2.2.3 Coagulation Factor
- 2.2.4 Immune Globulin
- 2.2.5 Other
- 2.3 Blood Plasma Derivatives by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Hospital
- 2.3.3 Retail Pharmacy
- 2.3.4 Other
- 2.4 Assumptions and Limitations
3 Blood Plasma Derivatives Breakdown Data by Type
- 3.1 Global Blood Plasma Derivatives Historic Market Size by Type (2021-2026)
- 3.2 Global Blood Plasma Derivatives Forecasted Market Size by Type (2027-2032)
4 Blood Plasma Derivatives Breakdown Data by Application
- 4.1 Global Blood Plasma Derivatives Historic Market Size by Application (2021-2026)
- 4.2 Global Blood Plasma Derivatives Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Blood Plasma Derivatives Market Perspective (2021-2032)
- 5.2 Global Blood Plasma Derivatives Growth Trends by Region
- 5.2.1 Global Blood Plasma Derivatives Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Blood Plasma Derivatives Historic Market Size by Region (2021-2026)
- 5.2.3 Blood Plasma Derivatives Forecasted Market Size by Region (2027-2032)
- 5.3 Blood Plasma Derivatives Market Dynamics
- 5.3.1 Blood Plasma Derivatives Industry Trends
- 5.3.2 Blood Plasma Derivatives Market Drivers
- 5.3.3 Blood Plasma Derivatives Market Challenges
- 5.3.4 Blood Plasma Derivatives Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Blood Plasma Derivatives Players by Revenue
- 6.1.1 Global Top Blood Plasma Derivatives Players by Revenue (2021-2026)
- 6.1.2 Global Blood Plasma Derivatives Revenue Market Share by Players (2021-2026)
- 6.2 Global Blood Plasma Derivatives Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Blood Plasma Derivatives Head Office and Area Served
- 6.4 Global Blood Plasma Derivatives Players, Product Type & Application
- 6.5 Global Blood Plasma Derivatives Manufacturers Established Date
- 6.6 Global Blood Plasma Derivatives Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Blood Plasma Derivatives Market Size (2021-2032)
- 7.2 North America Blood Plasma Derivatives Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Blood Plasma Derivatives Market Size by Country (2021-2026)
- 7.4 North America Blood Plasma Derivatives Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Blood Plasma Derivatives Market Size (2021-2032)
- 8.2 Europe Blood Plasma Derivatives Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Blood Plasma Derivatives Market Size by Country (2021-2026)
- 8.4 Europe Blood Plasma Derivatives Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Blood Plasma Derivatives Market Size (2021-2032)
- 9.2 Asia-Pacific Blood Plasma Derivatives Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Blood Plasma Derivatives Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Blood Plasma Derivatives Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Blood Plasma Derivatives Market Size (2021-2032)
- 10.2 South America Blood Plasma Derivatives Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Blood Plasma Derivatives Market Size by Country (2021-2026)
- 10.4 South America Blood Plasma Derivatives Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Blood Plasma Derivatives Market Size (2021-2032)
- 11.2 Middle East & Africa Blood Plasma Derivatives Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Blood Plasma Derivatives Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Blood Plasma Derivatives Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Yuanda Shuyang
- 12.1.1 Yuanda Shuyang Company Information
- 12.1.2 Yuanda Shuyang Business Overview
- 12.1.3 Yuanda Shuyang Revenue in Blood Plasma Derivatives Business (2021-2026)
- 12.1.4 Yuanda Shuyang Blood Plasma Derivatives Product Portfolio
- 12.1.5 Yuanda Shuyang Recent Developments
- 12.2 Takeda
- 12.2.1 Takeda Company Information
- 12.2.2 Takeda Business Overview
- 12.2.3 Takeda Revenue in Blood Plasma Derivatives Business (2021-2026)
- 12.2.4 Takeda Blood Plasma Derivatives Product Portfolio
- 12.2.5 Takeda Recent Developments
- 12.3 Weiguang Bio
- 12.3.1 Weiguang Bio Company Information
- 12.3.2 Weiguang Bio Business Overview
- 12.3.3 Weiguang Bio Revenue in Blood Plasma Derivatives Business (2021-2026)
- 12.3.4 Weiguang Bio Blood Plasma Derivatives Product Portfolio
- 12.3.5 Weiguang Bio Recent Developments
- 12.4 Tiantan Bio
- 12.4.1 Tiantan Bio Company Information
- 12.4.2 Tiantan Bio Business Overview
- 12.4.3 Tiantan Bio Revenue in Blood Plasma Derivatives Business (2021-2026)
- 12.4.4 Tiantan Bio Blood Plasma Derivatives Product Portfolio
- 12.4.5 Tiantan Bio Recent Developments
- 12.5 CBPO
- 12.5.1 CBPO Company Information
- 12.5.2 CBPO Business Overview
- 12.5.3 CBPO Revenue in Blood Plasma Derivatives Business (2021-2026)
- 12.5.4 CBPO Blood Plasma Derivatives Product Portfolio
- 12.5.5 CBPO Recent Developments
- 12.6 Shuanglin Bio
- 12.6.1 Shuanglin Bio Company Information
- 12.6.2 Shuanglin Bio Business Overview
- 12.6.3 Shuanglin Bio Revenue in Blood Plasma Derivatives Business (2021-2026)
- 12.6.4 Shuanglin Bio Blood Plasma Derivatives Product Portfolio
- 12.6.5 Shuanglin Bio Recent Developments
- 12.7 RAAS
- 12.7.1 RAAS Company Information
- 12.7.2 RAAS Business Overview
- 12.7.3 RAAS Revenue in Blood Plasma Derivatives Business (2021-2026)
- 12.7.4 RAAS Blood Plasma Derivatives Product Portfolio
- 12.7.5 RAAS Recent Developments
- 12.8 Nanyue Bio
- 12.8.1 Nanyue Bio Company Information
- 12.8.2 Nanyue Bio Business Overview
- 12.8.3 Nanyue Bio Revenue in Blood Plasma Derivatives Business (2021-2026)
- 12.8.4 Nanyue Bio Blood Plasma Derivatives Product Portfolio
- 12.8.5 Nanyue Bio Recent Developments
- 12.9 Hualan Bio
- 12.9.1 Hualan Bio Company Information
- 12.9.2 Hualan Bio Business Overview
- 12.9.3 Hualan Bio Revenue in Blood Plasma Derivatives Business (2021-2026)
- 12.9.4 Hualan Bio Blood Plasma Derivatives Product Portfolio
- 12.9.5 Hualan Bio Recent Developments
- 12.10 Boya Bio
- 12.10.1 Boya Bio Company Information
- 12.10.2 Boya Bio Business Overview
- 12.10.3 Boya Bio Revenue in Blood Plasma Derivatives Business (2021-2026)
- 12.10.4 Boya Bio Blood Plasma Derivatives Product Portfolio
- 12.10.5 Boya Bio Recent Developments
- 12.11 Octapharma
- 12.11.1 Octapharma Company Information
- 12.11.2 Octapharma Business Overview
- 12.11.3 Octapharma Revenue in Blood Plasma Derivatives Business (2021-2026)
- 12.11.4 Octapharma Blood Plasma Derivatives Product Portfolio
- 12.11.5 Octapharma Recent Developments
- 12.12 LFB Group
- 12.12.1 LFB Group Company Information
- 12.12.2 LFB Group Business Overview
- 12.12.3 LFB Group Revenue in Blood Plasma Derivatives Business (2021-2026)
- 12.12.4 LFB Group Blood Plasma Derivatives Product Portfolio
- 12.12.5 LFB Group Recent Developments
- 12.13 KM Biologics
- 12.13.1 KM Biologics Company Information
- 12.13.2 KM Biologics Business Overview
- 12.13.3 KM Biologics Revenue in Blood Plasma Derivatives Business (2021-2026)
- 12.13.4 KM Biologics Blood Plasma Derivatives Product Portfolio
- 12.13.5 KM Biologics Recent Developments
- 12.14 Kedrion
- 12.14.1 Kedrion Company Information
- 12.14.2 Kedrion Business Overview
- 12.14.3 Kedrion Revenue in Blood Plasma Derivatives Business (2021-2026)
- 12.14.4 Kedrion Blood Plasma Derivatives Product Portfolio
- 12.14.5 Kedrion Recent Developments
- 12.15 Grifols
- 12.15.1 Grifols Company Information
- 12.15.2 Grifols Business Overview
- 12.15.3 Grifols Revenue in Blood Plasma Derivatives Business (2021-2026)
- 12.15.4 Grifols Blood Plasma Derivatives Product Portfolio
- 12.15.5 Grifols Recent Developments
- 12.16 CSL
- 12.16.1 CSL Company Information
- 12.16.2 CSL Business Overview
- 12.16.3 CSL Revenue in Blood Plasma Derivatives Business (2021-2026)
- 12.16.4 CSL Blood Plasma Derivatives Product Portfolio
- 12.16.5 CSL Recent Developments
- 12.17 BPL
- 12.17.1 BPL Company Information
- 12.17.2 BPL Business Overview
- 12.17.3 BPL Revenue in Blood Plasma Derivatives Business (2021-2026)
- 12.17.4 BPL Blood Plasma Derivatives Product Portfolio
- 12.17.5 BPL Recent Developments
- 12.18 Biotest
- 12.18.1 Biotest Company Information
- 12.18.2 Biotest Business Overview
- 12.18.3 Biotest Revenue in Blood Plasma Derivatives Business (2021-2026)
- 12.18.4 Biotest Blood Plasma Derivatives Product Portfolio
- 12.18.5 Biotest Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst